VAS score reduction greater at week 16 for addition of nemolizumab versus placebo to topical agents. For patients with atopic dermatitis and moderate-to-severe pruritus, nemolizumab results in a greater reduction …
-
-
Can dermatology employers require employees to receive the COVID-19 vaccine?
-
THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS
-
Expression of retinoid receptors in hand eczema.
-
S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants
-
Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.
